DSIP Side Effects: What the Studies Recorded, What Is Reported Now, and What to Tell Your Physician

The product this page covers:

At 1 mg/mL, 0.25 mL is 0.25 mg of DSIP per dose (arithmetic from the vial strength, on a U-100 insulin syringe), and a vial holds 20 doses, about four weeks of weeknight dosing. Your own directions are set by your physician after reviewing your intake and are printed on the vial. Prices are all-in: medication, physician review, refill management and shipping, with no membership fee. DSIP is compounded by a PCAB-accredited, FDA-registered US 503A pharmacy. Compounded medications are not FDA approved.

DSIP is a nine-amino-acid peptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from the blood of sleeping rabbits and named in 1977. The FDA uses its international name, emideltide. It is not a hormone, not a steroid and not related to melatonin.

The most useful fact for the side-effect question is that it is not a sedative. In the first healthy-volunteer study, subjects felt a "pressure to sleep" during the infusion, but two hours later showed no sleepiness and no impaired performance. The 1980s work described changes in the shape of sleep, fewer awakenings and less light sleep, rather than sedation. And DSIP disappears fast: a half-life of about eight minutes in human plasma, because blood enzymes clip it apart. Any effect is a signalling event, not a drug level held through the night.

Neither substitutes for the other. Do not stop a prescription hypnotic without your prescriber.

DSIP's human data is unusual for a compounded peptide: there are randomised, double-blind, placebo-controlled studies in people. They are small, old, and all used intravenous infusion.

The FDA counted roughly 209 people across all the human work, all treated intravenously, none after 1992. The longest human course on record is fifteen days.

These are reported clinically, not measured against placebo, so there are no reliable percentages. Any source quoting rates for DSIP injection side effects is citing something that does not exist in the published literature. Prescribers generally treat the first vial as an assessment window, ideally with a sleep diary; "nothing" is an answer for your physician, not a reason to change the dose yourself.

DSIP was placed in Category 2 of the FDA's 503A bulk drug substances list in 2023. On 15 April 2026 the FDA removed emideltide from Category 2, effective 22 April 2026, and its listing now records that "FDA has not identified safety-related information regarding emideltide for the proposed route of administration."

The FDA's briefing document for its advisory committee cited missing characterisation data in the nominations, human effectiveness evidence it judged "inconclusive and at best preliminary," and the absence of any safety data for the subcutaneous route. On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 6 in favour, 7 against, with 1 abstention, and so did not recommend adding emideltide to the 503A Bulks List. That vote is advisory, and the FDA has not issued a final determination. DSIP remains legal to prescribe and dispense, and it is not an FDA-approved drug.

The practical reading for side effects: the FDA found no safety signal, and it also found no safety data for the way DSIP is prescribed today. Both are true.

DSIP is injected under the skin, into the fat layer, usually in the abdomen or thigh, rotating sites, at bedtime on weeknights. That schedule is a prescribing convention, not one taken from the trials, which used intravenous infusion. A small lump that appears as you inject and softens over a day or two is fluid in the tissue; one that appears days later and is warm or spreading needs a same-day message. Technique is in how to inject peptides safely.

DSIP ships refrigerated with ice packs, with sterile syringes and alcohol prep pads. Do not freeze it. Beyond-use dating runs from first puncture and is printed on the label.

• a headache that persists beyond the first doses
• dreams vivid enough to disturb your sleep
• any next-day grogginess, light-headedness or fainting
• sleep getting worse rather than steadier
• you start, stop or change any opioid, sedative, sleep medication or blood-pressure medicine

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

The SERENITY Blend combines DSIP with Selank, CJC-1295 and ipamorelin. The DSIP points on this page apply to it, and so do the side effects of the other components. Selank is sometimes described as causing early fatigue or flatness, and the growth-hormone-axis peptides have their own profile. The blend is covered in what is the SERENITY blend.

DSIP was reported as well tolerated in every small human study, the FDA's adverse event database holds no reports for it, and no withdrawal or rebound insomnia was seen where it was measured. That is a clean record as far as it goes. It does not go far: about 209 people, all intravenous, the longest course fifteen days, nothing since 1992, and no human safety data at all for subcutaneous injection or for months of use. The safety picture on this page is the absence of reported harm in small, old studies, not a demonstration of long-term safety. The general picture for this category is in peptide side effects: what to watch for.

DSIP cannot be bought legitimately without a prescription. Products sold "for research use only" have no accountable pharmacy behind their identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications, sleep and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance, and prescribes DSIP in every state except Oklahoma, plus DC The step-by-step page is how to get DSIP prescribed online.